Diana DeGette

Most enrollees reported satisfaction with their health plans, although some concerns exist.

There are thousands of families in the United States who are benefiting in the way my family has, and I am going to fight until the end to make sure that they can keep these benefits.

We have had historic reductions in the number of uninsured people in this country.

Highlighting solutions or making important course corrections requires a willing Congress and at this point my colleagues on the other side of the aisle don't seem to be willing to admit to the public that the law has actually helped…

What I am saying is it is time to stop having this kabuki dance over and over again, and it is time to start figuring out how we can fix the Affordable Care Act.

Do you know if it covers treatment for deja vu, because there seems to be a mass outbreak of that on Capitol Hill when it comes to the ACA.

Nobody wants to see waste, fraud, and abuse. We are opposed on a bipartisan basis to waste, fraud, and abuse.

I just want to clarify a couple of things that we have been talking about this morning.

If this CSR fund is struck down by the court then 6.4 million people will lose their subsidies.

I really don't question the motives of the majority here. I think it is in the congressional prerogative to file a lawsuit if Congress believes that the Administration has overstepped its constitutional bounds.

For the alleged 'most transparent Administration in history,' this Administration is trying its utmost to avoid Congressional scrutiny.

If they think what they are doing is legal, then come before this committee and explain it.

Oversight is critical to a functioning democracy.

The Constitution clearly states that the power of the purse lies not with the Executive, but with the Congress.

There are clear problems with the law if the Administration must violate the Constitution to keep the law afloat.

I wish you would, thanks, because maybe that can help illuminate--yes, Dr. Hatchett?

We need a full panoply of investment in the research, the basic science, the drug discovery and drug development that lasts.

I want to talk about how we can incentivize development of new antibiotics.

This report last month about the superbug has been quite concerning to all of us.

We have been worried for quite some time here in Congress and at the agencies about the risk of resistant antibiotics.

The goal of the biopharmaceutical accelerator will be in collaboration with our partners at NIAID.

The bacterium's resistance to colistin is particularly concerning because in this country physicians use colistin as the treatment of last resort.

The instability in the market is I don't think unexpected.

Myself and Congressman Bilirakis have introduced a bill that talks about lowering drug costs through competition.

1.7 million Floridians now have been able to access affordable coverage.